Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specif...
Gespeichert in:
| Veröffentlicht in: | Journal of Cancer 2016-01, Vol.7 (11), p.1383-1387 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1387 |
|---|---|
| container_issue | 11 |
| container_start_page | 1383 |
| container_title | Journal of Cancer |
| container_volume | 7 |
| creator | Damm-Welk, Christine Siddiqi, Faraz Fischer, Matthias Hero, Barbara Narayanan, Vignesh Camidge, David Ross Harris, Michael Burke, Amos Lehrnbecher, Thomas Pulford, Karen Oschlies, Ilske Siebert, Reiner Turner, Suzanne Woessmann, Wilhelm |
| description | Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK. |
| doi_str_mv | 10.7150/jca.15238 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4964121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1807895713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-5ee937eaf17564ed81c2495f7c3d4c97cf56e64a83500131d6d5006a99f76a903</originalsourceid><addsrcrecordid>eNpVkc1OAjEUhRujEYIsfAHTpS4Gp9N2Ot2YEII_EZCFrJvS6UDJ0OJ0QH17O4IEu-g9yf167k0PANco7jFE4_uVkj1EE5ydgTbKMIt4mpLzE90CXe9XcTiYJ4zgS9AKJbyluA1mfVubqD96hY2Yu9xoD42FU1kbbWsPP029hKEfTZ03tdlpOJalWVhpVYNOXA2HX5tKe2_sAk6m48bsClwUsvS6e6gdMHscvg-eo9Hb08ugP4oUZrSOqNYcMy0LxGhKdJ4hlRBOC6ZwThRnqqCpTonMMI1jhFGe5kGkkvOChTvGHfCw991s52udq7BxJUuxqcxaVt_CSSP-d6xZioXbCcJTghIUDG4PBpX72Gpfi7XxSpeltNptvUBZzDJOGcIBvdujqnLeV7o4jkGxaJIQIQnxm0Rgb073OpJ__45_AEClgvI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1807895713</pqid></control><display><type>article</type><title>Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Damm-Welk, Christine ; Siddiqi, Faraz ; Fischer, Matthias ; Hero, Barbara ; Narayanan, Vignesh ; Camidge, David Ross ; Harris, Michael ; Burke, Amos ; Lehrnbecher, Thomas ; Pulford, Karen ; Oschlies, Ilske ; Siebert, Reiner ; Turner, Suzanne ; Woessmann, Wilhelm</creator><creatorcontrib>Damm-Welk, Christine ; Siddiqi, Faraz ; Fischer, Matthias ; Hero, Barbara ; Narayanan, Vignesh ; Camidge, David Ross ; Harris, Michael ; Burke, Amos ; Lehrnbecher, Thomas ; Pulford, Karen ; Oschlies, Ilske ; Siebert, Reiner ; Turner, Suzanne ; Woessmann, Wilhelm</creatorcontrib><description>Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.15238</identifier><identifier>PMID: 27471553</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Short Research Communication</subject><ispartof>Journal of Cancer, 2016-01, Vol.7 (11), p.1383-1387</ispartof><rights>Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-5ee937eaf17564ed81c2495f7c3d4c97cf56e64a83500131d6d5006a99f76a903</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964121/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964121/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27471553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Damm-Welk, Christine</creatorcontrib><creatorcontrib>Siddiqi, Faraz</creatorcontrib><creatorcontrib>Fischer, Matthias</creatorcontrib><creatorcontrib>Hero, Barbara</creatorcontrib><creatorcontrib>Narayanan, Vignesh</creatorcontrib><creatorcontrib>Camidge, David Ross</creatorcontrib><creatorcontrib>Harris, Michael</creatorcontrib><creatorcontrib>Burke, Amos</creatorcontrib><creatorcontrib>Lehrnbecher, Thomas</creatorcontrib><creatorcontrib>Pulford, Karen</creatorcontrib><creatorcontrib>Oschlies, Ilske</creatorcontrib><creatorcontrib>Siebert, Reiner</creatorcontrib><creatorcontrib>Turner, Suzanne</creatorcontrib><creatorcontrib>Woessmann, Wilhelm</creatorcontrib><title>Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.</description><subject>Short Research Communication</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkc1OAjEUhRujEYIsfAHTpS4Gp9N2Ot2YEII_EZCFrJvS6UDJ0OJ0QH17O4IEu-g9yf167k0PANco7jFE4_uVkj1EE5ydgTbKMIt4mpLzE90CXe9XcTiYJ4zgS9AKJbyluA1mfVubqD96hY2Yu9xoD42FU1kbbWsPP029hKEfTZ03tdlpOJalWVhpVYNOXA2HX5tKe2_sAk6m48bsClwUsvS6e6gdMHscvg-eo9Hb08ugP4oUZrSOqNYcMy0LxGhKdJ4hlRBOC6ZwThRnqqCpTonMMI1jhFGe5kGkkvOChTvGHfCw991s52udq7BxJUuxqcxaVt_CSSP-d6xZioXbCcJTghIUDG4PBpX72Gpfi7XxSpeltNptvUBZzDJOGcIBvdujqnLeV7o4jkGxaJIQIQnxm0Rgb073OpJ__45_AEClgvI</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Damm-Welk, Christine</creator><creator>Siddiqi, Faraz</creator><creator>Fischer, Matthias</creator><creator>Hero, Barbara</creator><creator>Narayanan, Vignesh</creator><creator>Camidge, David Ross</creator><creator>Harris, Michael</creator><creator>Burke, Amos</creator><creator>Lehrnbecher, Thomas</creator><creator>Pulford, Karen</creator><creator>Oschlies, Ilske</creator><creator>Siebert, Reiner</creator><creator>Turner, Suzanne</creator><creator>Woessmann, Wilhelm</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK</title><author>Damm-Welk, Christine ; Siddiqi, Faraz ; Fischer, Matthias ; Hero, Barbara ; Narayanan, Vignesh ; Camidge, David Ross ; Harris, Michael ; Burke, Amos ; Lehrnbecher, Thomas ; Pulford, Karen ; Oschlies, Ilske ; Siebert, Reiner ; Turner, Suzanne ; Woessmann, Wilhelm</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-5ee937eaf17564ed81c2495f7c3d4c97cf56e64a83500131d6d5006a99f76a903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Short Research Communication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Damm-Welk, Christine</creatorcontrib><creatorcontrib>Siddiqi, Faraz</creatorcontrib><creatorcontrib>Fischer, Matthias</creatorcontrib><creatorcontrib>Hero, Barbara</creatorcontrib><creatorcontrib>Narayanan, Vignesh</creatorcontrib><creatorcontrib>Camidge, David Ross</creatorcontrib><creatorcontrib>Harris, Michael</creatorcontrib><creatorcontrib>Burke, Amos</creatorcontrib><creatorcontrib>Lehrnbecher, Thomas</creatorcontrib><creatorcontrib>Pulford, Karen</creatorcontrib><creatorcontrib>Oschlies, Ilske</creatorcontrib><creatorcontrib>Siebert, Reiner</creatorcontrib><creatorcontrib>Turner, Suzanne</creatorcontrib><creatorcontrib>Woessmann, Wilhelm</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Damm-Welk, Christine</au><au>Siddiqi, Faraz</au><au>Fischer, Matthias</au><au>Hero, Barbara</au><au>Narayanan, Vignesh</au><au>Camidge, David Ross</au><au>Harris, Michael</au><au>Burke, Amos</au><au>Lehrnbecher, Thomas</au><au>Pulford, Karen</au><au>Oschlies, Ilske</au><au>Siebert, Reiner</au><au>Turner, Suzanne</au><au>Woessmann, Wilhelm</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>7</volume><issue>11</issue><spage>1383</spage><epage>1387</epage><pages>1383-1387</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>27471553</pmid><doi>10.7150/jca.15238</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1837-9664 |
| ispartof | Journal of Cancer, 2016-01, Vol.7 (11), p.1383-1387 |
| issn | 1837-9664 1837-9664 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4964121 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Short Research Communication |
| title | Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A08%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-ALK%20Antibodies%20in%20Patients%20with%20ALK-Positive%20Malignancies%20Not%20Expressing%20NPM-ALK&rft.jtitle=Journal%20of%20Cancer&rft.au=Damm-Welk,%20Christine&rft.date=2016-01-01&rft.volume=7&rft.issue=11&rft.spage=1383&rft.epage=1387&rft.pages=1383-1387&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.15238&rft_dat=%3Cproquest_pubme%3E1807895713%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1807895713&rft_id=info:pmid/27471553&rfr_iscdi=true |